

TERMS AND CONDITIONS

1. SAMPLE OF THE MEDICINE SHALL BE PROVIDED WHEN CALLED FOR. SPLITTING OF QUANTITY SHALL BE AT THE DISCRETION OF PURCHASER.
2. OFFER FROM MANUFACTURERS OR THEIR MARKETING ORGANISATION IF ANY SHALL BE ACCEPTED. THE MANUFACTURERS MAY INDICATE THEIR INSTITUTIONAL AUTHORISED DISTRIBUTOR'S NAME REGION WISE TO SUPPLY THE MEDICINE.
3. IN THE EVENT OF PARTY QUOTING FOR A PRODUCT MARKETED BY THEM THE DETAILS OF THE ORIGINAL MANUFACTURERS AND MRP OF THE PRODUCT SHOULD BE INDICATED IN THE QUOTATION. PLEASE ALSO MENTION THE % DIFFERENCE BETWEEN MRP & QUOTED RATE.
4. MEDICINE WOULD BE LAB TESTED FOR EFFICACY AND TESTING CHARGES TO BE BORNE BY THE SUPPLIER. THE SUPPLY SHOULD BE MADE WITHIN 45 DAYS FROM THE DATE OF RECEIPT OF PURCHASE ORDER. SAME BRAND OF MEDICINE FOR WHICH QUOTATION HAS BEEN SUBMITTED SHOULD BE AVAILABLE IN THE MARKET.
5. SUPPLIER / MANUFACTURER SHOULD MENTION MRP OF THE MEDICINE FOR WHICH THEY HAVE QUOTED.
6. MRP AND BRAND NAME OF THE PRODUCT MUST BE INDICATED IN THE QUOTATIONS. ELSE OFFER WILL BE REJECTED.
7. **FOR INJECTIONS TENDER :**
WHEREVER INJECTIONS ARE IN DRY POWDER FORM, QUOTATION SHOULD BE SUBMITTED FOR " DRY POWDER INJECTIONS WITH REQUIRED DILUENT / RECONSTITUENT".
8. MANUFACTURER MUST ADHERE TO THE SPECIFIED PACK SIZE MENTIONED IN THE ENQUIRY. THE QUOTATION IS LIABLE TO BE REJECTED IF DIFFERENT PACK SIZE IS QUOTED.
9. QUOTATION SHOULD BE STRICTLY AS PER OUR REQUIRED SPECIFICATION/COMBINATION/STRENGTH AND IT SHOULD BE CLEARLY MENTIONED IN THE QUOTATION. QUOTATION WITHOUT/COMINATION/STRENGTH WILL BE REJECTED.
10. THE RATE SHOULD BE AS PER PACK SIZE MENTIONED IN THE TENDER.
11. SHELF LIFE TO BE MENTIONED IN THE QUOTATION.
12. THE SUPPLY SHOULD BE FROM THE LATEST SINGLE BATCH WITH LONGER EXPIRY.
13. EACH CARTON / CONTAINER / STRIP SHOULD BE STAMPED WITH "**FOR GOVERNMENT SUPPLY**".
14. ANALYTICAL TEST REPORTS SHOULD BE SUBMITTED ALONG WITH SUPPLIES.
15. IN THE EVENT OF ALL MEDICINES NOT CONSUMED WELL BEFORE SIX MONTHS OF THE EXPIRY DATE. THE SAME WOULD BE RETURNED TO MANUFACTURER AND IT SHALL BE THE RESPONSIBILITY OF THE MANUFACTURER TO COLLECT SUCH MEDICINES AND ALSO ENSURE FOR EFFECTING FREE REPLACEMENT OF SUCH MEDICINES WITH MAXIMUM SHELF LIFE. IF THE MANUFACTURER IS UNABLE TO REPLACE THE DRUGS WITH MAXIMUM SHELF LIFE, THE PURCHASE COST OF THE MEDICINES SHALL BE REFUNDED BY THE MANUFACTURER.